Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientstagelifemetforminmmol
  Phrases that lowered it: pressureparticipantsbloodmm hginvestigate
• Collaborators: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: 44.4% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 1.3% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue NCT01794429 · started 2013 · scored riskier than 38% of active trials completed
• A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range NCT06041217 · started 2023 · scored riskier than 8% of active trials completed
• A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes NCT04032197 · started 2019 · scored riskier than 14% of active trials completed
• A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight NCT05649137 · started 2023 · scored riskier than 8% of active trials completed
• Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes NCT05040971 · started 2021 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.